Milestone Pharmaceuticals (MIST) Cash & Equivalents (2018 - 2026)

Milestone Pharmaceuticals' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $71.3 million for Q1 2026.

• Quarterly Cash & Equivalents changed N/A year-over-year to $71.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.3 million (changed N/A YoY) and the FY2025 annual result came in at $73.0 million, up 188.56% from the prior year.
• Cash & Equivalents was $71.3 million for Q1 2026 at Milestone Pharmaceuticals, down from $73.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $101.0 million in Q1 2023 and bottomed at $7.6 million in Q4 2022.
• A 5-year average of $55.9 million and a median of $63.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 93.31% — and 2025, when it surged 188.56%.
• Milestone Pharmaceuticals' Cash & Equivalents stood at $7.6 million in 2022, then jumped by 80.2% to $13.8 million in 2023, then jumped by 83.97% to $25.3 million in 2024, then jumped by 188.56% to $73.0 million in 2025, then declined by 2.37% to $71.3 million in 2026.
• Business Quant data shows MIST's Cash & Equivalents at $71.3 million in Q1 2026, $73.0 million in Q4 2025, and $82.6 million in Q3 2025.